Identification and functional characterisation of a rare MTTP variant underlying hereditary non-alcoholic fatty liver disease.

Background and aims: Non-alcoholic fatty liver disease (NAFLD) is a complex trait that has a global prevalence estimated as 25%. We aimed to identify the genetic variant underlying a four-generation family with progressive NAFLD leading to cirrhosis, decompensation and development of hepatocellular carcinoma in the absence of common risk factors such as obesity and type 2 diabetes. Methods: Exome sequencing and genome comparisons were used to identify the likely causal variant. We extensively characterised the clinical phenotype and post-prandial metabolic responses of family members with the identified novel variant in comparison to healthy non-carriers and wild type patients with NAFLD. Variant-expressing hepatocyte-like cells (HLCs) were derived from human induced pluripotent stem cells generated from homozygous donor skin fibroblasts. The phenotype was assessed using imaging, targeted RNA analysis and molecular expression arrays. Results: We identified a rare causal variant in MTTP, c.1691T>C p.I564T (rs745447480) encoding microsomal triglyceride transfer protein (MTP) associated with progressive non-alcoholic fatty liver disease, unrelated to metabolic syndrome. Although other described mutations in MTTP cause abetalipoproteinemia, neither homozygotes nor heterozygotes exhibited characteristic manifestations of this severe disease. HLCs derived from a homozygote donor had lower lipoprotein ApoB secretion, compared to wild type cells. Cytoplasmic triglyceride accumulation in HLCs triggered endoplasmic reticulum stress, secretion of pro-inflammatory mediators and production of reactive oxygen species. Conclusion: We have identified and characterized a rare causal variant in MTTP and homozygosity for MTTP p.I564T is associated with progressive NAFLD without any other manifestations of abetalipoproteinemia.


Introduction
Non-alcoholic fatty liver disease (NAFLD) is a complex trait encompassing a spectrum of accumulation of triglyceride-rich lipid droplets within the hepatocytes (steatosis), non-alcoholic steatohepatitis (NASH; having ballooning degeneration and inflammatory cell infiltration), varying degree and pattern of fibrosis leading to cirrhosis and its decompensation, as well as hepatocellular carcinoma (HCC). With rising incidence of obesity and type 2 diabetes, NAFLD is now the most common chronic liver disease with an estimated 25% population prevalence globally. 1 Genome-wide association studies (GWAS) have identified a number of genetic risk variants for NAFLD including PNPLA3 p.I148M (c.444C>G, rs738409) and TM6SF2 p.E167K (c.449C>T, rs58542926), both of which have robust associations with disease phenotypes via functional pathobiological pathways. 2,3 Accretion of Patatin-like phospholipase domain-containing protein 3, PNPLA3, 148M on lipid droplets sequesters coactivators, resulting in reduced lipolysis and lipophagy and transmembrane protein 6 superfamily member 2, TM6SF2, 167K variant impairs VLDL lipidation; accumulation of triglycerides in both contexts is associated with progressive liver disease. 2 The putative role of microsomal transfer protein (MTP), a lipid transfer protein localized in the endoplasmic reticulum of hepatocytes involved in lipidation and assembly of ApoB containing lipoproteins in the development of NAFLD, has been investigated and MTTP variants have been linked with susceptibility to NAFLD. [4][5][6] Rare, loss-of-function mutations in MTTP can result in the recessive disorder abetalipoproteinemia (ABL) 7 (OMIM:200100), where MTP deficiency causes defective lipoprotein biosynthesis having multiple severe effects including liver steatosis and fibrosis. [8][9][10] However, hereditary progressive NAFLD associated with a MTTP variant, without any manifestations of abetalipoproteinemia, has not been previously described.
Here we have clinically characterised a large four generation family found to have a rare MTTP variant resulting in progressive NAFLD, with consequent cirrhosis, liver failure and hepatocellular carcinoma in homozygotes. We evaluated post-prandial . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07. 22.21260356 doi: medRxiv preprint metabolic responses in carriers of the novel MTTP p.I564T variant compared to noncarriers. We used hepatocyte-like cells (HLCs) derived from human induced pluripotent stem cells (hiPSCs) generated from donor skin fibroblasts from carriers and non-carriers of the MTTP variant, as a stable reproducible model for understanding the effect of the variant on the cellular phenotype. This has enabled us to understand how this can drive steatosis and NAFLD and therefore linking genotype to phenotype in hereditary NAFLD.
We show that the I564T variant is associated with increased sequestration of lipids in cultured MTTP (VAR/VAR) HLCs derived from hiPSCs. These HLCs have elevated endoplasmic reticulum (ER) stress, activated pro-inflammatory signalling pathways including NFκB, and secrete pro-inflammatory mediators. This coincides with reduced levels of MTP and apolipoprotein B-100 (ApoB-100), increased production of reactive oxygen species (ROS) and superoxide, and alterations to mitochondrial respiration. This confirms the role of functional genetic variants in maintaining hepatic lipid homeostasis via lipoprotein secretion. This model also provides important insights into how chronic hepatic steatosis can progress to hepatocyte dysfunction, inflammation, cancer and eventually organ failure.

Patient Investigations
Clinical investigations followed standard clinical care and included 6-month followup as required. Family members were screened at joint hepatology-genetics clinics within NHS Trusts between 2013-2020.

Human Samples
The clinical studies were reviewed by the National Research Ethics Service

Meal-response study
Participants were recruited to the study at Queens Medical Centre, Nottingham

Genetic Variant Identification
DNA was derived from blood except the 3 EXCEED study samples 11 which were derived from saliva. Whole exome sequencing (single batch with 3 replicates) mean depth of coverage was 42-66×. Exome enrichment was done in 3 batches using NimbleGen SeqCap EZ Exome v3.0 (64Mb). Samples were sequenced using 100bp paired-end sequencing on the Illumina HiSeq2000 (each sample sequenced in 2 lanes) and validated by Sanger sequencing. Both NAFLD cases and controls were present in each pair of lanes and in each batch to minimise confounding.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021.

Genotyping
Genotype validation was done using Sanger sequencing for MTTP alleles (Source Bioscience Ltd) or PCR restriction fragment analysis using primers listed in Supplemental Methods.

Metabolite analyses
Plasma lipoproteins were separated by sequential non-equilibrium densitygradient ultracentrifugation 23 . EDTA plasma was pipetted into quick-seal ultracentrifuge tubes (Beckman Coulter) and topped up with 1.006g/ml potassium bromide (KBr).
Sealed tubes were centrifuged in a Beckman Optima ultracentrifuge XL-70 under vacuum at 12°C for 20min at 12,000rpm. Afterwards, each tube was opened using a tube slicer (Kontron). The top chylomicron layer was taken and made up to 2ml with KBr solution and stored at -20°C. The lower lipoprotein layer was then transferred to fresh ultracentrifuge tubes and centrifuged for 16h at 39,000rpm with full acceleration and no break. Following ultracentrifugation the top VLDL layer was removed, this and the lower layer were separately stored at -20°C.
Blood metabolites were quantified using calibrated Horiba auto-analyser and reagents following standard manufacturer validated protocols (Horiba ABX). Serum ApoB was determined by turbidimetry using ABX Pentra Apo reagent. Serum cholesterol was quantified using cholesterol BP diagnostic reagent, and colorimetry with HDL Direct CP and LDL Direct CP reagents used for LDL and HDL-cholesterol. Glucose was quantified in plasma by colorimetry using Glucose PAP CP reagent. Colorimetry with Triglycerides CP reagent was used to quantify serum triglycerides. Plasma free fatty acids were measured using Wako NEFA C enzymatic colour test method (Wako Chemicals GmbH). Serum insulin was quantified using Human Insulin specific RAI kit (Millipore).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint

Isolation and culture of human dermal fibroblasts
Two 2mm skin punch biopsies were obtained from study participant 1, a healthy male, and participant J, (homozygous for rs745447480 I564T). Primary human dermal fibroblasts were established via by explants culture in DMEM medium supplemented with 2% Antibiotic-Antimycotic; 10% FBS; 1% GlutaMAX; 1% NEAA and 1% penicillin/streptomycin. Fibroblast medium was refreshed every 2-3 days, cells were split at 1:3-1:6 using 0.25% Trypsin-EDTA for 3min at 37°C when 80% confluent. All reagents were from Gibco (Thermo Fisher). All cell lines tested negative for mycoplasma contamination using the EZ-PCR Mycoplasma Test Kit (Biological Industries) prior to reprogramming.

Fibroblast reprogramming, hiPSC maintenance and differentiation
Human skin fibroblasts were reprogrammed using CytoTune iPS 2.0 Sendai Reprogramming Kit (Invitrogen, Thermo Fisher) in accordance with the manufacturer's guidelines. Mesoderm and ectoderm differentiation of hiPSCs was as described previously 24 , 25 . All cells were differentiated into hepatocytes as described previously 26 .
Karyotyping 30 metaphase spreads from exponentially growing hiPSC cultures were analysed by conventional karyotyping 27 (Nottingham University Hospitals).

Protein analyses
Human Apolipoprotein B-100 (apoB-100) was determined in culture supernatants by ELISA (Sigma-Aldrich) according to the manufacturer's recommendations (in duplicate). Human NFκB Pathway, Phospho-Kinase and XL Cytokine Array Kits were used as specified by the manufacturer (R&D Systems).

Imaging and detection of cellular and mitochondrial ROS
Cells were stained with Nile Red, Hoechst, DAPI or antibodies listed in Supplemental Methods. Mitochondrial content of HLCs were visualised using 100nM . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021. MitoTracker green FM or MitoTracker deep red FM and intracellular reactive oxygen species (ROS) and mitochondrial superoxide production were assessed using 2.5μM CellROX green or 2.5μM MitoSox Red following manufacturer's guidance (Invitrogen).

Mitochondrial respiration analysis
To assess mitochondrial respiration, culture medium was replaced with 200µl Seahorse XF base medium supplemented with 10mM glucose, 1mM sodium pyruvate and 2mM L-glutamine at 37°C without CO2 for 1h prior to measurements using the Seahorse

RT-qPCR Gene expression analysis
Quantitative real-time PCR (qPCR) was carried out as described previously 28 . Fold changes in expression were calculated using comparative ΔΔCt method standardised against the housekeeping gene PBGD, data were shown as mean of Ct values ± standard error of mean (SEM).

RNA sequencing
RNA sequencing and bioinformatics analysis were performed at the Babraham Institute (Cambridge, UK). Sequencing was done using the Illumina HiSeq2500 system (depth = 30 million). Reads were mapped to Ensembl GRCh38.p10 using Hisat2 (v2.1.0). Analysis used SeqMonk (1.46.0) software, with read counts determined using RNA-Seq pipeline and differential expression analysis using DESeq2 (1.28.1) package.
Data was trimmed with Trim Galore v0.6.2 (default parameters), aligned to the GRCh38 using Hisat2 v2.1.0 (option "--sp 1000,1000" to prevent soft-clipping) then seeded with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. introns from gene models from Ensembl v87. Alignments with a MAPQ score of <20 were discarded.
Per gene expression was quantitated against gene models from Ensembl v97 counting read overlaps to any exon of each gene. Only alignments on the opposite strand to the gene being measured were counted. For normalised expression visualisation log2 Reads per million reads of library (log2RPM) values were calculated, and corrected using size factor normalisation based on genes with replicate measurements.
An initial set of differentially expressed genes was calculated from raw counts using the DESeq2 package. Genes with a FDR of <0.05 were retained. This list was further filtered using an expression normalised fold change z-score, again with a cut-off of FDR <0.05.

Statistical analysis
Data are shown as means ±standard error of the mean unless stated otherwise.
Statistical analyses were performed using Graph Pad Prism version 8 (La Jolla, CA, USA) software. One-way ANOVA followed by Dunnett's multiple comparison test were used to compare data from samples grouped by a single factor. Two-way ANOVA followed by Sidak's post hoc test was used to compare data grouped by two factors. All authors had access to the study data and reviewed and approved the final manuscript.

Clinical presentation of family
A four-generation family with recent South Asian ancestry was referred to the Clinical Genetics Department for genetic counselling after three individuals from the same generation developed hepatocellular carcinoma (HCC). One parent of that generation (B in Table 1) presented with NAFLD symptoms and was diagnosed with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint cirrhosis; the other parent (A) had no history of NAFLD or metabolic syndrome.
Clinical investigations found all their children had NAFLD diagnosis as adults with progression to NASH, cirrhosis (in seven) and HCC (in four) suggestive of a high conversion rate between NAFLD to cirrhosis and hepatocellular carcinoma. Only one of the affected individuals had a body mass index >30 and instances of type 2 diabetes, hypertension or hyperlipidaemia within the family were not linked with the presence or severity of disease ( Table 1).

Identification of rare MTTP variant allele associated with diagnosis
Functional variants which were unique to affected family members were identified by whole exome sequencing of twelve affected individuals (B, C, D, E, F, H, J, K, L, N, O, P in Table 1) by comparison with nine unaffected South Asian controls (including spouses of four affected individuals), three unrelated population-based participants from the EXCEED study 11 , and two unrelated South Asian individuals with cholangiocarcinoma) and databases of genetic variation identified in the general population. We identified a missense variant: genomic NC_000004.12:g.99608899T>C, NM_000253.2:c.1691T>C, protein NP_000244.2:p.Ile564Thr, abbreviated to I564T, in MTTP that was unique to affected family members ( Figure 1) and fully segregated with disease phenotype in those individuals analysed. All six homozygous individuals developed cirrhosis and three also developed hepatocellular carcinoma, while some heterozygotes had no diagnosed disease ( Table 1). Presence of both heterozygotes and homozygotes for the rare allele in among the siblings in the family implies that individual A must also have carried at least one copy of the variant allele. The presence of fatty liver in wild type individual I is suggested to be incidental, relating to lifestyle factors.
This I564T variant has been previously described in combination with a second rare variant (IVS1+1G>C), manifesting as severe fatty liver in an atypical case of ABL in Japan 29 but was reported to have 'mild effect' in the mother carrying I564T alone. The I564T variant is described in the NCBI database 30 as rs745447480 with allele frequency <1.6 x 10 5 (gnomAD exomes v2.1.1) present in 4 European cases. Other family . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. (rs738409) and TM6SF2 (rs58542926) associated with NAFLD was also determined (Supplementary Table 2). None of the 83 NAFLD patients tested from the Trivandrum Indian cohort 31 had the MTTP p.I564T variant allele.

Postprandial responses in affected individuals
The MTTP p.I564T variant is predicted to have a potential impact on MTP function  Table 1) while testing of a stored pre-transplant serum sample from individual J and clinical data revealed that levels were also substantially lower before receiving a replacement liver where the gene is likely restored (Table 1).
We also compared levels of serum ApoB-100, the isoform associated with VLDL, in the MTP564-TT homozygotes F and J, with that of wild type MTP564-II control, participant 1 (Supplementary Table 3 Of note, lipoprotein-associated lipid levels are also lower in participant 7, a NAFLD patient who is homozygous for the PNPLA3 rs738409 variant (PNPLA3-MM) which has been linked to a relative reduction in large VLDL secretion 35 ( Supplementary Figures 2A   and 3F). Circulating free fatty acids, glucose and insulin levels in the family members were unremarkable (Supplementary Figures 1C, 1D and 4).

Generation of wild-type and MTTP (VAR/VAR) hiPSCs for disease modelling
To elucidate the mechanisms driving hepatic steatosis in homozygous MTP564-TT patients, we generated hiPSCs and differentiated them into hepatocytes termed . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Figure 5D). Lastly, to ensure reprogramming had not caused any major chromosomal abnormalities we confirmed the karyotype as normal for both hiPSC lines (Supplementary Figure 5E and   5F).

Wild-type and MTTP (VAR/VAR) hiPSCs differentiate comparably but MTP levels are lower in the cell line expressing the variant protein and lipoprotein secretion is impaired
Next, to ensure our model would not be biased by different differentiation efficiency of our hiPSC lines, we differentiated cells from the study donors 1 and J into HLCs to compare morphology and gene expression profiles. 26 Both cell lines appeared morphologically similar during all stages of differentiation and generated a monolayer of HLCs by day 21 ( Figure 4A). Gene expression in both cell lines was similar at each of the developmental time points including definitive endoderm, foregut endoderm, and hepatoblast cells. Expression of genes associated with a mature hepatocyte phenotype (HNF4α, ALB, A1AT) was not significantly different between the two cell lines ( Figure   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.  Figure 4D) and that the MTP I564T variant in these patients affects ApoB-100 processing and lipid trafficking.

MTTP (VAR/VAR) HLCs inherently accumulate intracellular lipids
We cultured the derived HLCs to observe any phenotypic differences between the 2 cell lines. After growth for 48h in hepatocyte culture medium, MTTP (WT/WT) cells maintained a normal hepatocyte morphology and they accumulated a few apparent lipid droplets in the cytoplasmic space. In contrast, the MTTP (VAR/VAR) HLCs appeared to develop discrete lipid droplets and clusters of many very small lipid droplets throughout the cytoplasm. To confirm these were lipid droplets we used the lipophilic dyes Oil-Red-O (Supplementary Figure 7C) and Nile Red to stain lipid vesicles demonstrating differences in the amount of accumulated lipid. Quantification of Nile Red fluorescence intensity showed levels were more than 4-fold higher in MTTP (VAR/VAR) HLCs, (Figure 4E and 4F).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint This is consistent with the proposed reduced VLDL secretion in cells expressing MTP564-TT, restricting removal of intracellular triglycerides.

Increased generation of ROS and altered mitochondrial respiration in MTTP (VAR/VAR) HLCs
Hepatic free fatty acids can be converted to triglyceride for storage as cytoplasmic droplets or secreted as VLDL, or else directly metabolised via mitochondrial β-oxidation. Therefore, impaired MTP functionality restricting lipid secretion, thus increasing the availability of fatty acids, may impact on mitochondrial activities. Of  5B) consistent with increased fatty acid metabolism. This was further evidenced using mitochondrial stress testing measuring the oxygen consumption rate in live cells which found that MTTP (VAR/VAR) HLCs had significantly higher basal and maximal mitochondrial respiration compared to mitochondria from the wild type cell line ( Figure 4I).

Increased NFB signalling, inflammation, ER stress and secretion of proinflammatory mediators in MTTP (VAR/VAR) HLCs
Impaired lipid trafficking and lipoprotein assembly incurred as a consequence of reduced MTP functionality is likely to cause a range of cellular responses including ER stress and inflammation. Steatosis is specifically associated with hepatic inflammation including activation of NFκB intracellular signalling pathways and secretion of proinflammatory mediators. 37 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

MTTP (VAR/VAR) HLCs show increased expression of ECM remodelling and lipid metabolising genes.
Lastly, to better understand genome wide changes in gene expression in MTTP (VAR/VAR) and MTTP (WT/WT) HLCs we performed mRNA-sequencing following 2 days of culture and spontaneous lipid accumulation. Bioinformatics revealed 472 genes differentially . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021.

Discussion
We have identified and characterised a rare MTTP variant (p.I564T) associated with an inherited form of non-alcoholic fatty liver disease, in a four-generation family.
Our investigation has revealed a variant resulting in decreased ApoB-containing lipoprotein secretion in homozygotes (demonstrated in persons E, F and J of the family studied), rather than abetalipoproteinemia where ApoB is undetectable ( Figure 2B, Table   1) 7,9,[38][39][40] . Levels of ApoB in heterozygotes K, Q and a further five heterozygotes in generation II were normal. Although other carriages of this variant have been described, no phenotypic characteristics related to these are previously reported 29 , gnomAD).
Protein modelling ( Figure 1B; Ensembl) suggests the substitution affects the protein structure but does not lie in the active site or in functional regions previously described. 22,41,42 The T-C change possibly impacts on mRNA or protein stability/turnover or alter partner interactions which would reduce or alter its activity resulting in a different phenotype to that of abetalipoproteinemia. Presentation of homozygote cases is clearly distinct from ABL 8, 38 supporting suggested subtle phenotype whereby impact is limited to liver lipid imbalance. This provides potential for treatment through reduced dietary fat intake and makes it an attractive model for cellular consequences of lipid accumulation.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. Phenotyping studies demonstrated contrasting levels of fasting serum ApoB levels as well as VLDL secretion following meal challenge in the two MTTP-564TT family members; while both of the biomarkers were substantially low in untreated individual F, these were in the normal range in the liver transplant recipient J ( Figure 2B; Table 1).
Previously, the MTTP -493 variant (rs1800591) G allele associated with reduced MTP function has been associated with NAFLD susceptibility in a meta-analysis of 11 casecontrol studies. 6 Also an association study in non-diabetic patients with NASH (and controls) found GG homozygotes had significantly higher plasma triglycerides, intestinal and hepatic large VLDL and oxidised LDL than GG/GT group. 43 Additionally, a candidate gene study found that in healthy men with elevated triglyceride levels, the MTTP p.H297Q variant was associated with higher ApoB levels. 44 All of the five MTP564-IT heterozygous individuals showed ApoB and lipoprotein levels within the normal range. This is consistent with previous report that a single copy of MTTP may be sufficient for normal functionality. 45 Disruption of ApoB biosynthesis and associated VLDL secretion has been widely described with a spectrum of consequences linked to characterised pathologies. 10 The underlying mechanisms are inherently linked to nutritional intake with diets high in fats (increasing hepatic fat content) and carbohydrate (increasing hepatic de novo lipogenesis) resulting in hyperlipidemia.
Hepatic lipid balance is dependent on secretion of VLDL which is restricted by availability/activity of MTP, so any variants with altered activities are likely to have metabolic effects. The small number of people carrying the rare variant available for analysis is a limitation of this work.
Overall, VLDL secretion may increase with hepatic steatosis related to metabolic syndrome. 46 However, in people carrying the PNPLA3 rs738409 G allele, a relatively decreased VLDL secretion per amount of liver fat (particularly triglyceride-rich, large VLDL) has been reported in non-diabetics 35 and PNPLA3-mediated lipid remodelling linked to NAFLD development through unknown mechanisms. 47,48 VLDL secretion is also lowered in TM6SF2 T carriers 33,34,49 . In our study, postprandial VLDL secretion, the . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint predominant postprandial lipoprotein associated with hyperlipidemia 50 , was found to be reduced in cases homozygous for TM6SF2 or PNPLA3 but fasting ApoB levels were normal in contrast with MTTP p.I564T homozygosity where we observed both a reduced level of ApoB and VLDL-associated lipids.
In addition to demonstrating the functional consequences of MTTP p.I564T variant, the HLCs derived from hiPSCs provide a disease model for early stage NAFLD, beyond this triglyceride accumulation. However, we acknowledge that this model is derived from a single homozygote and compared to cells from an unrelated wild type donor. Studies have shown a link between the amount of steatosis, fibrosis development and liver disease mortality 51 with lipid metabolism acting as the initiator of progression to NASH. 52 Although sequestered triglycerides are suggested to provide a protective buffer, lipotoxicity may arise from metabolites such as saturated fatty acids leading to pathway components (including ACC-1/2, FXR/FGF19/FXR4, and SCD-1) being tested as therapeutic targets. 53 Increased mitochondrial fatty acid β-oxidation may provide a protective response but uncontrolled results in the generation of ROS which can be a major driver of oxidative stress and cellular dysfunction ( Figure 4I, Figure 6).
We show that as lipid accumulation increases, hepatocytes have increased ER stress, activate pro-inflammatory signalling pathways including NFκB, P53, eNOS and secrete pro-inflammatory mediators. This coincides with increased production of reactive oxygen species, superoxide production and alterations to mitochondrial respiration driving the disease progression leading to cirrhosis and hepatocellular carcinoma as seen among the family members. Similar findings were reported in cardiomyocytes derived in an MTTP pR46G variant model. 36 Excessive lipid accumulation in hepatocytes can serve as substrates for the generation of lipotoxic species. One of the major consequences of hepatic lipid metabolism is mitochondrial β-oxidation and esterification to form triglycerides which can serve as a protective mechanism against lipotoxicity in hepatocytes. However, if lipid accumulation is in excess of the β-oxidation capacity, such . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Data Sharing Statement
The data that support the findings of this study are available on request from the corresponding author. Exome sequence data will be available for restricted access via The European Genome-phenome Archive.

Acknowledgements
The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. We thank all the research participants particularly the family involved. We are grateful to the study teams of the EXCEED study, the Trivandrum cohort and NASH study for their contributions. We are grateful to the clinical team at University Hospitals Leicester NHS Trust for clinical workup and acknowledge support from the late Roger Williams. We thank the highthroughput genomics group at the Wellcome Trust Centre for Human Genetics for the generation of the sequence data. We thank Michael Steward for generating illustration of MTP, and thank Sally Cordon and Ian Macdonald for assistance with metabolic analysis and Melanie Lingaya and Calum Greenhalgh for technical support. We thank Ester . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021.  Tables   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021. ;  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021.   Tables 1 and 2). Participants are grouped according to age and gender matched to each family member (white bars are healthy volunteers (HV); grey bars are NAFLD patients). Genes are shown in parentheses where participant is homozygous for the effect allele (PNPLA3 rs738409; TM6SF2 rs58542926). NAFLD= non-alcoholic fatty liver disease; FL=Fatty Liver. (C) ApoB-100 levels in serum from study participants fasted and approximately 3 hours after eating.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 25, 2021.   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 25, 2021. ; https://doi.org/10.1101/2021.07.22.21260356 doi: medRxiv preprint